The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure
Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis
About this trial
This is an interventional treatment trial for Acute on Chronic Hepatic Failure
Eligibility Criteria
Inclusion Criteria: Able to communicate effectively with investigators and sign the informed consent form (ICF) voluntarily. Age: ≥ 18 years and ≤ 65 years. Body weight: ≥ 40kg; Met the criteria of ACLF in the early and middle stages in screening period (Guidelines for the Diagnosis and Treatment of Liverfilture (2018 Edition)): base on chronic liver disease, acute jaundice deepened and coagulation dysfunction caused by various inducements, manifested as extreme fatigue, with obvious gastrointestinal symptoms such as anorexia, vomiting, abdominal distention, etc; Progressive deepening of jaundice, serum TBil ≥ 171 μmol/L or increase ≥ 17.1 μmol/L daily; with bleeding tendencies or manifestations (bleeding spots or ecchymosis), or 20%<PTA ≤ 40% (or 1.5 ≤ INR<2.6), and other reasons excluded. Exclusion Criteria: Subjects with primary or metastatic liver cancer. Subjects with severe esophageal/gastric varices and high risk of bleeding, with positive red signs, or with previous active bleeding, as indicated by gastroscopy or imaging examination results. Pneumonia refer to the diagnostic criteria of the American Society of Infectious Diseases/American Thoracic Society for adult severe pneumonia in 2007), abdominal infection (after reasonable antibiotic treatment, there are still Peritonitis manifestations or white blood cells in ascites>0.1 × 10 9/L), etc. Subjects with serious uncontrolled infections, including sepsis, septic shock, severe pneumonia (refers to the diagnostic criteria of the American Society of Infectious Diseases/American Thoracic Society for adult severe pneumonia in 2007), abdominal infection (exist Peritonitis manifestations or white blood cells in ascites>0.1 × 10 9/L after reasonable antibiotic treatment), etc;
Sites / Locations
- Beijing You'an Hospital affiliated to Capital Medical UniversityRecruiting
Arms of the Study
Arm 1
Experimental
HepaCure
Patients will receive Hepacure treatment on top of DPMAS